RLMD logo

RELMADA THERAPEUTICS INC

RLMDNASDAQ
🏆 #3150 by market capEarnings Nov 11US Equity
$3.73▼ $0.07 (−1.97%)
Market closed · at close
🔔
Track RLMD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.0%
7d▼ 1.2%
14d▼ 11.7%
30d▼ 14.4%
ytd▼ 22.7%
1y▲ 85.1%
🏦Market Cap
$391M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$3.69 – $3.78
52-Week Range
$1.80 – $8.00
Volume
$2.95B
Avg Volume
$3.35B
Shares Outstanding
104.9M
Next Earnings
Dec 6, 2026

Fundamentals Snapshot

Annual Revenue
$38M
Last Q Revenue
$10M
P/E Ratio
-4.1
P/S Ratio
0.0x
EPS (TTM)
$-0.55
Dividend Yield
0.00%
Dilution (1yr)
+126.2%

Why Investors Own RLMD

  • ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 41% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RLMD logo

RELMADA THERAPEUTICS INC

RLMD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$59M▼ −29.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$46M▼ −11.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
68.3M▲ +126.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▼ −$360K YoY
StockOtter · stockotter.space

About RELMADA THERAPEUTICS INC

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Ratings

ⓘ
Consensus
Buy
11 analysts
Strong Buy4
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Reuters·2h ago

RELMADA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift RLMD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

RELMADA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.